|Bid||4.8500 x 1000|
|Ask||5.0800 x 1200|
|Day's range||4.7000 - 4.9900|
|52-week range||4.5100 - 11.2400|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||31 Oct 2014|
|1y target est||21.75|
Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
The big shareholder groups in Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) have power over the company. Large...